ProQR Therapeutics N.V (PRQR) Income from Continuing Operations: 2021-2025
Historic Income from Continuing Operations for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.
- ProQR Therapeutics N.V's Income from Continuing Operations fell 44.50% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 79.87%. This contributed to the annual value of -$29.7 million for FY2024, which is 1.11% up from last year.
- As of Q3 2025, ProQR Therapeutics N.V's Income from Continuing Operations stood at -$12.9 million, which was up 6.53% from -$13.8 million recorded in Q2 2025.
- ProQR Therapeutics N.V's 5-year Income from Continuing Operations high stood at -$3.1 million for Q2 2024, and its period low was -$23.4 million during Q3 2022.
- Its 3-year average for Income from Continuing Operations is -$8.9 million, with a median of -$8.9 million in 2024.
- As far as peak fluctuations go, ProQR Therapeutics N.V's Income from Continuing Operations surged by 74.62% in 2023, and later tumbled by 342.01% in 2025.
- ProQR Therapeutics N.V's Income from Continuing Operations (Quarterly) stood at -$20.8 million in 2021, then skyrocketed by 34.89% to -$13.6 million in 2022, then soared by 56.56% to -$5.9 million in 2023, then crashed by 68.70% to -$9.9 million in 2024, then tumbled by 44.50% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$13.8 million for Q2 2025, and -$10.6 million during Q1 2025.